William Rosenfeld, MD, AAN 2022: Phase III post-hoc analysis of cenobamate for focal-onset seizures
Cenobamate is approved in the United States for focal-onset seizures (partial-onset seizures) in adults both as adjunctive and monotherapy. In the EU, cenobamate is approved as adjunctive therapy for focal-onset seizures with or without secondary generalization for adult patients who have not been adequately controlled with at least two antiseizure medications. Dr. William Rosenfeld (Comprehensive Epilepsy Care Centre for Children and Adults, St. Louis, MO, USA) discusses pooled analysis of data investigating cenobamate for the treatment of focal-onset seizures and how the incidence of treatment-related cognitive and psychiatric events compare with other anti-seizure medications.
The abstract entitled ‘Efficacy of Cenobamate by Focal Seizure Subtypes: Post-hoc Analysis of a Phase 3, Multicenter, Open-Label Study’ was presented at the American Academy of Neurology (AAN) annual meeting, April 2-7, 2022.
- Could you tell us a little about cenobamate, the pooled analysis of data you are presenting, and its findings? (0:07)
- How did the incidence of cognitive and psychiatric treatment-related adverse events compare with that of other anti-seizure medications? (7:46)
- What are your take home messages? (16:15)
Disclosures: William Rosenfeld is a consultant for Arvelle and SK Life Science, Inc.; receives grant/research support from SK Life Science, Inc., and UCB Pharma; and receives honoraria/honorarium from SK Life Science, Inc.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Share this Video
Related Videos In Epilepsy
Jacqueline French, AAN 2023: XEN1101, a novel potassium channel modulator for the treatment of focal epilepsy
In this interview with touchNEUROLOGY, Prof. Jacqueline French (Comprehensive Epilepsy Center, New York University, New York, NY, US) discusses the needs of adults with focal epilepsy and the mechanisms of action of XEN1101, a novel, potent, selective Kv7.2/7.3 potassium channel. The abstract entitled “XEN1101, a Novel Potassium Channel Modulator: Interim Data From an Ongoing, Long-Term, […]
Jacqueline French, AAN 2023: X-TOLE phase 2b open-label extension trial of XEN1101 in focal epilepsy – interim data
The randomized, double-blind, placebo-controlled phase IIb study X-TOLE (NCT03796962) is investigating the efficacy of XEN1101, a novel potassium channel modulator, in adults with focal epilepsy. In this interview with touchNEUROLOGY, Prof. Jacqueline French (Comprehensive Epilepsy Center, New York University, New York, NY, US) discusses this clinical trial and the outcomes of its open-label extension. The […]
Galia Wilson, Dravet Syndrome UK: DSUK Objectives, directions and support for families and people living with Dravet syndrome
Dravet Syndrome (DS) is a rare neurological condition, beginning in infancy and lasting a lifetime. touchNEUROLOGY were joined by Galia Wilson, Chair and Trustee of Dravet Syndrome UK (DSUK), a charity created in 2008 by a group of parents who came together looking for support, resources and information relating to the neurological condition. In this interview, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!